ERBB2 and breast carcinoma: Another promising intrathecal treatment for HER2-positive breast cancer with LM is trastuzumab; case reports have shown that intrathecal trastuzumab is a feasible treatment with limited toxicity [10], but more data are needed to determine its actual efficacy.